Faculty Collaboration Database

Serum profiling to distinguish early- and late-stage ovarian cancer patients from disease-free individuals. Cancer Invest 2012 Feb;30(2):189-97

Date

12/14/2011

Pubmed ID

22149058

DOI

10.3109/07357907.2011.636115

Scopus ID

2-s2.0-84863397497 (requires institutional sign-in at Scopus site)   6 Citations

Abstract

Sera mass spectrometry (MS) peak differences were analyzed from 35 ovarian cancer patients and 16 disease-free individuals. "Leave one out" cross validation was used to assign "% cancer peaks" in control and ovarian cancer sera samples. Sera MS discriminated stage I/II and stage III/V ovarian cancer patients versus controls with ROC curve area values of 0.82 and 0.92. Test sensitivities for ovarian cancer stage I/II and III/V were 80% and 93% respectively. These results indicate that MS is useful for distinguishing sera from early-stage ovarian cancer patients, and has potential as a test for early detection of this disease.

Author List

Hocker JR, Bishop EA, Lightfoot SA, Lerner MR, Peyton MD, Brackett DJ, Hanas RJ, McMeekin DS, Walker JL, Hanas JS

MESH terms used to index this publication - Major topics in bold

Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
Case-Control Studies
Disease-Free Survival
Female
Humans
Mass Spectrometry
Middle Aged
Neoplasm Staging
Ovarian Neoplasms